Cargando…
A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC
INTRODUCTION: The real-world effectiveness of combination treatment with cytotoxic chemotherapy and programmed cell death protein-1 or programmed death-ligand 1 inhibitor for NSCLC, especially for the elderly (aged ≥75 y) or those with poor performance status (≥2), has not been fully elucidated. We...
Autores principales: | Fujimoto, Daichi, Miura, Satoru, Yoshimura, Kenichi, Wakuda, Kazushige, Oya, Yuko, Haratani, Koji, Itoh, Shoichi, Uemura, Takehiro, Morinaga, Ryotaro, Takahama, Takayuki, Nakashima, Kazuhisa, Tachihara, Motoko, Saito, Go, Tanizaki, Junko, Otsubo, Kohei, Ikeda, Satoshi, Matsumoto, Hirotaka, Hara, Satoshi, Hata, Akito, Masuda, Takeshi, Yamamoto, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8819387/ https://www.ncbi.nlm.nih.gov/pubmed/35146460 http://dx.doi.org/10.1016/j.jtocrr.2021.100265 |
Ejemplares similares
-
Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer
por: Fujimoto, Daichi, et al.
Publicado: (2023) -
Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L)
por: Miyawaki, Taichi, et al.
Publicado: (2021) -
Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced NSCLC: A Multicenter Prospective Single Arm Phase 2 Trial: DRAGON Study (WJOG9416L)
por: Tachihara, Motoko, et al.
Publicado: (2023) -
Non‐parallel anti‐tumour effects of pembrolizumab: a case of cardial tamponade
por: Tachihara, Motoko, et al.
Publicado: (2019) -
Using the neutrophil‐to‐lymphocyte ratio to predict the outcome of individuals with nonsquamous non‐small cell lung cancer receiving pembrolizumab plus platinum and pemetrexed
por: Imai, Hisao, et al.
Publicado: (2023)